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Propofol is a short-acting intravenous anesthetic commonly utilised in the intensive care unit (ICU) for 
sedation of mechanically ventilated patients. The rapid onset and termination of action make it an 
attractive drug for use in the ICU. The safety profile of propofol is well established. However, there are 
potential adverse reactions associated with the drug. This review discusses the pharmacology, admin- 
istration and adverse effects associated with propofol with which clinicians who administer propofol 
should be familiar. 
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Propofol (Diprivan, Zeneca Pharmaceuticals, 
Wilmington, DE, U.S.A.) is an intravenous sedative- 
hypnotic recently approved by the Food and Drug 
Administration for sedation of mechanically venti- 
lated patients in the intensive care unit (ICU) (l-3). 
Propofol has been utilised for many years as an 
anesthetic agent for surgical procedures. However, 
the drug remains unfamiliar to many ICU personnel. 
Many features of propofol make it attractive for 
short-term use (less than 5 days) in the general ICU 
setting: rapid onset of action, short duration of 
clinical effect, ease of titration, rapid cessation of 
effect, limited accumulation of the parent compound 
or metabolites, and minimal adverse effects (4-6). 
Propofol differs from other sedatives’ commonly 
utilised in the ICU, such as benzodiazepines and 
opiates, in chemical structure, sedative properties and 
side-effect profile. All practitioners who care for the 
critically ill should be familiar with the basic clinical 
indications, pharmacology, administration and 
potential adverse effects associated with propofol. 
Indications 
Propofol has been utilised for many types of surgical 
procedures, including cardiovascular, ophthalmic and 
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neurosurgical, as well as a variety of outpatient 
surgical procedures. Other clinical situations in which 
propofol has been utilised include conscious sedation, 
electroconvulsive therapy (7), cardioversion, tracheal 
intubation (8,9) and mechanical ventilation (10). 
There have been reports of the efficacy of propofol 
for chemotherapy-induced emesis (1 I), as well as an 
antipruritic in patients with intractable pruritis due to 
liver disease (12). Propofol has also been utilised 
effectively to treat status epilepticus (13) as well as 
tetanus (14). Table 1 displays some of the non- 
surgical clinical indications of propofol. 
Clinical Pharmacology 
Propofol (2,6-diisopropylphenol) is an alkyl phenol 
derivative that possesses sedative and hypnotic 
properties. The drug has little water solubility and, 
therefore, is formulated in an oil-in-water emulsion 
consisting of 1.0% propofol, 10% soybean oil, 2.25% 
glycerol and 1.2% egg phosphatide. The drug is 
contraindicated in patients with hypersensitivity to 
eggs (4,6). Propofol possesses very little analgesic 
properties and is unrelated to opioids, benzodi- 
azepines and tranquilizers. Propofol usually produces 
hypnosis within 1 min of intravenous administration, 
the approximate time for one arm-brain circulation to 
occur (4). 
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TABLE 1. Non-surgical uses of propofol 
Tracheal intubation 
Mechanical ventilation 
Bronchoscopy 
Cardioversion 
Electroconvulsive therapy 
Chemotherapy associated emesis 
Liver disease induced pruritis 
Status epilepticus 
Tetanus 
PHARMACOKINETIC AND 
PHARMACODYNAMIC PROPERTIES 
Pharmacokinetics describes the rate and extent of 
drug handling by the body, namely absorption, dis- 
tribution, metabolism and excretion. Pharmacody- 
namics describes the pharmacologic responses the 
drug has on the body (6,16,17). The pharmacokinetic 
profile of propofol is characterised by its rapid tissue 
distribution from the blood and rapid clearance (15). 
Propofol is extremely lipophilic which accounts for its 
rapid distribution to highly perfused tissues as heart, 
lung, brain and liver (6). The half-life of propofol is 
approximately 1.8-4.1 min (18). The rapid tissue dis- 
tribution and short half-life account for the drug’s 
rapid onset and short duration of action. After cessa- 
tion of infusion, blood concentrations decline swiftly, 
with an average decrease of 50% in 10 min. Clinically, 
this accounts for rapid recovery times in most 
patients once the drug is discontinued (lo-30 min); 
however, after prolonged infusions, the terminal 
half-life may increase to 3 days (4). The volume 
of distribution of propofol is between 209 and 
1008 1 kg - ‘, due to its lipophilic nature. Approxi- 
mately 98% of propofol is plasma-protein bound and 
is mainly hepatically metabolised to produce inactive 
water-soluble sulfate and glucuronide conjugates that 
are excreted in the urine (6,19). Less than 0.3% of a 
dose is excreted in the urine and feces as the parent 
compound (4,15). There is no significant change in 
pharmacokinetics in patients with chronic liver dis- 
ease or chronic renal failure, making dosing adjust- 
ments unnecessary in these groups of patients. 
However, age does affect the kinetics of propofol, 
with elderly patients having a lower clearance rate 
than younger cohorts, reflecting the reduction in 
cardiac output and hepatic blood flow that occurs 
with aging (20,21). Hence, recommended dosages are 
lower in the elderly. 
The most clinically significant pharmacodynamic 
properties of propofol are referable to the neurologic, 
cardiovascular and respiratory systems. Propofol. 
produces rapid hypnosis and has synergistic activity 
when administered concurrently with barbiturates, 
benzodiazepines and opioids. The drug has anti- 
convulsant activity which is likely mediated by 
y-aminobutyric acid (GABA) receptors in the brain 
(15). Propofol decreases cerebral blood flow by up to 
50% with a concurrent decrease in intracranial pres- 
sure. Cerebral autoregulation, however, is preserved 
during propofol infusion (4) Cerebral metabolic 
oxygen requirements also decrease by l&36% (22). 
The main effect of propofol on the cardiovascular 
system is hypotension, which results primarily from a 
reduction in systemic vascular resistance (10,21). 
Reduction of systolic blood pressure by 30% of 
baseline values occurs in up to 26% of ICU patients. 
Propofol may also directly decrease cardiac output by 
depression of myocardial contractility (23). Hypovo- 
lemia and opioid use potentiate the hypotensive 
effects of propofol. Bradycardia occurs occasionally 
possibly due to drug action on the conduction system 
or autonomic nervous system (24). However, propo- 
fol rarely results in severe bradycardia or conduction 
abnormalities, but should be used with caution with 
other vagotonic drugs such as opioids. Propofol’s 
effects on the respiratory system include a reduction 
in minute ventilation, tidal volume and functional 
residual capacity (4,25). Since propofol is a respirat- 
ory depressant, caution should be used when it is 
administered with other agents, especially opioids, as 
apnea will occur in virtually all patients when these 
drugs are used concurrently (6). Propofol depresses 
pharyngeal reflexes and decreases jaw muscle tone, 
thus facilitating intubation, and may obviate need for 
paralysing agents during routine intubations (8,9). 
Propofol has little, if any, effect on liver or adrenal 
functions (10,15). 
Propofol in the ICU 
Propofol is an effective sedative agent for use in the 
ICU, especially for patients receiving mechanical 
ventilation. Propofol infusion in the ICU has been 
demonstrated to be safe and effective for patients 
requiring prolonged sedation (up to 5 days) during 
mechanical ventilation (10,26). Grounds et al. (26) 
compared propofol with midazolam for sedation in a 
group of 60 post-cardiac surgery patients, and 
showed that patients administered propofol generally 
recovered more rapidly from sedation. In this study, 
propofol patients regained spontaneous ventilation 
in an average of 9-5 min compared to 202 min for 
midazolam; times to extubation averaged 20 min for 
the propofol group and 237 min for the midazolam 
group. 
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Chamorro et al. (27) conducted a multicenter, 
randomised, prospective, non-blinded study compar- 
ing propofol with midazolam for sedation of patients 
in the ICU. The average duration of sedation was less 
for the propofol group (81 h) than the midazolam 
group (88 h). This study also demonstrated that 
propofol was a more effective sedative than 
midazolam for achieving patient synchrony with the 
ventilator. Patients administered propofol regained 
consciousness more rapidly than patients sedated 
with midazolam (27 min vs. 237 min). 
An ideal drug for ICU sedation has been described 
by one author as one that: produces sedation without 
cardiovascular or respiratory depression; does not 
influence the metabolism of other drugs; is metab- 
olised in a manner not dependent on hepatic or renal 
function; and has a short half-life without accumu- 
lation of the parent compound or its metabolites (28). 
Although no agent can simultaneously fulfill all of 
these ideal criteria, propofol has been proven useful 
in the critically ill population, especially in those 
patients with hepatic or renal failure. Also, rapid 
recovery of patients from sedation is important and, 
as shown in the studies noted above, may lead to 
easier extubation and, ultimately, shorter time spent 
on the ventilator. 
Dosing and Administration 
Dosing of propofol for mechanically ventilated ICU 
patients includes an initial bolus followed by a main- 
tenance infusion. The recommended loading dose is 
5-1Opg kg-‘min- ’ followed by an infusion rate 
titrated to the level of sedation. It is important to 
remember that propofol acts synergistically with 
midazolam in producing sedation, and doses may 
need adjustment if these drugs are used concurrently 
(29). Also, sedation should be discontinued in a 
manner similar to initiation to avoid anxiety and 
agitation which can occur when propofol is abruptly 
withdrawn. 
Propofol may be administered through a peripheral 
vein on the dorsum of the hand or antecubital fossa, 
but pain on injection is common when these sites are 
used. However, since propofol is a lipid emulsion, it is 
preferable to administer it through a central vein to 
minimise irritation and damage to peripheral veins 
(15). Since the lipid vehicle has been shown to sup- 
port bacterial growth, aseptic technique is mandatory 
(30-32). The manufacturer offers the following guide- 
lines for administration: disinfection of the rubber 
stopper with 70% isopropyl alcohol before spiking 
with sterile intravenous tubing; avoiding excessive 
manipulation of the line designated for propofol 
infusion; and discarding the vial and tubing within 
12 h after starting an infusion. Propofol contains no 
antimicrobials or preservatives so it is important that 
opened, unused propofol is discarded immediately 
(15,32). 
Adverse Reactions 
The safety profile of propofol is well established; 
however, there are adverse reactions with which clin- 
icians should be familiar (Table 2). The most com- 
mon adverse effect is pain on injection. As noted 
above, the central route of administration is pre- 
ferred, but when propofol is given peripherally, pain 
occurs in 31% of patients when the dorsum of the 
hand is used and in 8% when a vein in the antecubital 
fossa is used. If a peripheral vein is used, the incidence 
of pain can be reduced by injecting 10 mg of 1% 
lidocaine 10 s before propofol, or mixing it with 
propofol immediately before infusion (6,15). Propo- 
fol should be used with caution in patients who are 
hypotensive, hypovolemic or hemodynamically 
unstable since, as noted above, the drug may cause 
profound hypotension. However, in most patients, 
such hypotension is transient and responds to a 
decrease in the drug infusion rate. Furthermore, the 
drug should be avoided in patients who are not 
intubated and mechanically ventilated, due to its 
potential for respiratory depression and blunting of 
airway reflexes. Propofol should not be administered 
to pregnant or lactating patients since there are 
no well-controlled human studies in these groups. 
Adverse reactions on the cardiac and respiratory 
system include hypotension, bradycardia and respir- 
atory depression, and are discussed in the section of 
pharmacodynamic properties. 
Neuroexitatory events have been reported during 
propofol use, and include tremor, twitching and 
hiccups (15). Opisthotonos, a tetanic reaction in 
which the spine and extremities are hyperextended 
with the body resting on the head and heels, has 
occurred with propofol and is felt to be due to 
tolerance to GABA-induced central nervous system 
inhibition. Most cases of opisthotonos, however, 
occurred in conjunction with fentanyl during surgical 
procedures, and only two cases have been reported 
when propofol was used alone (33). Hallucinations 
have been rarely reported in association with 
propofol use (34). 
Anaphylaxis related to propofol has been reported, 
but it has been difficult to determine whether hyper- 
sensitivity is due to propofol or the lipid vehicle 
(35-37). One case report described a patient who 
experienced anaphylaxis to propofol and had a 
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TABLE 2. Adverse effects associated with propofol 
Cardiovascular Respiratory 
Hypotension Respiratory depression 
Bradycardia Decreased airway reflexes 
Enhanced CO, production 
Neurologic 
Tremor 
Twitching 
Hiccups 
Opisthotonus 
Metabolic Miscellaneous 
Hypertriglyceridemia 
Lactic acidosis 
Injection pain 
Anaphylaxis 
Sepsis 
Green urine 
Nausea/vomiting 
Pancreatitis 
Hives 
positive intradermal test to propofol solution, indi- 
cating that the drug itself may be responsible for 
anaphylaxis, although reaction to the lipid solution 
could not be excluded (37). Localised histamine 
release has been postulated to account for a patient 
who experienced a wheal-and-flare response at the 
site of propofol infusion (38). As noted previously, 
propofol should be avoided in patients with known 
egg hypersensitivity as the vehicle contains 1.2% egg 
phosphatide. 
Prolonged infusions of propofol in the ICU may 
increase carbon dioxide (CO,) production since the 
emulsion contains 0.1 g fat (1.1 kcal) ml - ‘. Excessive 
CO, levels may make weaning from mechanical ven- 
tilation difficult (39,40). The lipid content of the 
emulsion vehicle also increases serum triglyceride 
levels when infusions are prolonged (7-10 days). 
Blood specimens have been reported to be lipemic in 
children sedated with propofol as early as 2 days after 
initiation (41). Serum triglyceride and cholesterol 
levels in adults generally increase 3 days after com- 
mencing propofol, with triglyceride levels occasion- 
ally reaching four times normal (41,42). However, 
one study demonstrated no adverse effects related to 
a 3-day propofol infusion and noted no significant 
increase in serum lipid concentrations (43). Pancrea- 
titis is a well-known complication of hypertriglyceri- 
demia and remains a theoretical possibility with 
prolonged infusions. Serum lipid profiles should be 
monitored closely if propofol is continued past 72 h, 
especially in patients with underlying hypertriglyceri- 
demia. Pancreatitis has been recently reported in 
postoperative patients receiving propofol without 
other obvious predisposing factors, but was not con- 
clusively shown to be due to hypertriglyceridemia 
(44,45). Pancreatitis definitively associated with 
propofol remains to be established. 
Fatal metabolic acidosis has been reported in chil- 
dren receiving propofol for sedation (41,46). Most of 
these cases involved patients being sedated during 
mechanical ventilation for laryngotracheobronchitis, 
with death caused by cardiac arrest. The cause of 
metabolic acidosis in these patients was not deter- 
mined. It was postulated, however, that the lipid 
emulsion in propofol may impair hepatic clearance of 
lactate and lead to lactic acidosis, although none of 
these patients had serum lactate measured (41). A 
case of lactic acidosis was recently reported that was 
temporally associated with propofol in a young 
patient ventilated for an asthma exacerbation who 
had no other predisposing factors for lactic acidosis 
(1). Further studies will be needed to determine if 
lactic acidosis is indeed associated with propofol. 
Propofol has not been reported to be associated with 
significant liver injury (47). 
Sepsis occurring after infusion of contaminated 
bottles of propofol has been reported (31,32). Propo- 
fol supports growth of various micro-organisms 
including Gram positives, Gram negatives and Cun- 
dida albicans (Table 3). Propofol has been shown to 
support bacterial growth, with and without the lipid 
vehicle (15). A recent outbreak of propofol-associated 
bacteremia in seven hospitals between 1990 and 1993 
was reported. Bacteria isolated from these instances 
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TABLE 3. Micro-organisms linked to bacteremia with 
contaminated propofol 
Cctndida albicans 
Enterobacter agglomerans 
Klebsiella pneumoniae 
lMoraxella osolensis 
Serratia marcescens 
Staphylococcus aureus 
included Staphylococcus aureus, C. albicans, Morax- 
ella osloensis, Enterobacter agglomerans and Serratia 
marcescens (32). Veber et al. (48) reported four 
patients with Klebsiella pneumoniae sepsis associated 
with propofol in patients undergoing anesthesia for 
surgery, from a common vial that had been open for 
more than 12 h before use. As noted above, strict 
aseptic technique must be followed when propofol is 
administered in the ICU. 
Other less common adverse reactions to propofol 
include nausea, vomiting and green discoloration of 
urine. Propofol is a phenolic compound, a group of 
chemicals known for their tendency to cause green 
urine (49,50). A case of propofol abuse and depen- 
dence was reported (15). There have been two deaths 
reported from self-administered propofol overdose in 
doses of 400 and 1600 mg (51,52). Finally, the cost 
of propofol is extremely high, ranging from $380 to 
$1187 for a 24-h infusion, depending on the dose. 
Midazolam is priced similarly; however, lorazepam 
ranges from $36 to $379 for 24 h (4). 
Summary 
Propofol is a unique short-acting intravenous anes- 
thetic agent that is useful for sedation of mechanically 
ventilated patients in the ICU. It has many attractive 
features including rapid onset and termination of 
action, safety in patients with renal and hepatic 
disease, and ease of administration and titratability. 
However, there are potential adverse reactions associ- 
ated with the drug, most commonly hypotension. 
Other reported effects include bradycardia, central 
nervous system excitation, lactic acidosis, sepsis and 
green urine. Physicians who administer propofol to 
their patients should be familiar with these potential 
complications. 
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